Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 9, 2014, Pages 1800-1810

  Nalin, Lovisa ^a   Selvaraju, Ram K ^b   Velikyan, Irina ^b,c   Berglund, Marie ^b   Andréasson, Susanne ^a   Wikstrand, Anna ^a   Rydén, Anneli ^a   Lubberink, Mark ^b   Kandeel, Fouad ^d   Nyman, Görel ^a   Korsgren, Olle ^b   Eriksson, Olof ^b   Jensen Waern, Marianne ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Beta cell imaging; Exendin 4; GLP 1R; Pancreas; Perfusion; Pig

Indexed keywords

C PEPTIDE; CANINSULIN; GA DO3A VS CYS 40 EXTENDIN 4 GALLIUM 68; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; METOPROLOL TARTRATE; OXYGEN 15; PIG INSULIN; TRACER; UNCLASSIFIED DRUG; WATER; BIOLOGICAL MARKER; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER; CELL POPULATION; CLINICAL EXAMINATION; COMPARTMENT MODEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EXPERIMENTAL PIG; FEMALE; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN TREATMENT; KIDNEY PERFUSION; MALE; MEAN ARTERIAL PRESSURE; MICTURITION; NONHUMAN; PANCREAS PERFUSION; PET-CT SCANNER; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SUBCUTANEOUS FAT; TACHYCARDIA; THIRST; TISSUE PERFUSION; WEIGHT GAIN; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HEALTH; HEART RATE; KIDNEY; METABOLISM; PANCREAS ISLET BETA CELL; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; SWINE;

ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; HEALTH; HEART RATE; INSULIN; INSULIN-SECRETING CELLS; KIDNEY; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RECEPTORS, GLUCAGON; SWINE; WATER;

EID: 84906054064     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2745-3     Document Type: Article

References (37)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-21.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-31. (Pubitemid 28405191)
3. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14 Suppl 5:S1-85.
4. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care. 1993;16:157-77. (Pubitemid 23013841)
5. Souza F, Freeby M, Hultman K, Simpson N, Herron A, Witkowsky P, et al. Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas. Curr Med Chem. 2006;13:2761-73. (Pubitemid 44509723)
6. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem. 2008;56:841-51.
7. Leech CA, Dzhura I, Chepurny OG, Kang G, Schwede F, Genieser HG, et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic beta cells. Prog Biophys Mol Biol. 2011;107:236-47.
8. Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion frompancreatic beta-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15:15-27.
9. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88:220-4. (Pubitemid 36115169)
10. Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother. 2006;7:1055-64. (Pubitemid 43949943)
11. Selvaraju RK, Velikyan I, Johansson L, Wu Z, Todorov I, Shively J, et al. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J Nucl Med. 2013;54:1458-63.
12. Jensen-Waern M, Andersson M, Kruse R, Nilsson B, Larsson R, Korsgren O, et al. Effects of streptozotocin-induced diabetes in domestic pigs with focus on the amino acid metabolism. Lab Anim. 2009;43:249-54.
13. Manell E, Rydén A, Hedenqvist P, Jacobson M, Jensen-Waern M. Insulin treatment of streptozotocin-induced diabetes re-establishes the patterns in carbohydrate, fat and amino acid metabolism in growing pigs. Lab Anim. 2014.
14. Swindle MM, Smith AC. Comparative anatomy and physiology of the pig. Scand J Lab Anim Sci. 1998;25:11-21. (Pubitemid 128549607)
15. Yamaguchi T, Mullen Y, Watanabe Y, Nomura Y, Cass D, Brunicardi C. Isolation and Function of Islets from Young-Adult Pig Pancreas. Transplant Proc. 1992;24:1010-2.
16. Ambrisko TD, Hikasa Y, Sato K. Influence of medetomidine on stress-related neurohormonal and metabolic effects caused by butorphanol, fentanyl, and ketamine administration in dogs. Am J Vet Res. 2005;66:406-12. (Pubitemid 40553173)
17. Pfeiffer N, Ebner J, von Thaden A-K, Schuster T, Erhardt W, Baumgartner C. Cardiovascular effects of alfaxalone on hemodynamic function in pigs. Open Access Anim Physiol. 2013;2013:15-26.
18. van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, et al. Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CTscanner: test-retest variability in lung cancer. J Nucl Med. 2010;51:1684-90.
19. Fehmann HC, Habener JF. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line. FEBS Lett. 1991;279:335-40.
20. Fehmann HC, Janssen M, Göke B. Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells. Acta Diabetol. 1995;32:176-81.
21. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes. 1997;46:785-91. (Pubitemid 27188255)
22. Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med. 2010;51:1059-67.
23. Eich T, Eriksson O, Sundin A, Estrada S, Brandhorst D, Brandhorst H, et al. Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation. 2007;84:893-8. (Pubitemid 351338951)
24. Hildebrandt IJ, Su H, Weber WA. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J. 2008;49:17-26.
25. Momosaki S, Hatano K, Kawasumi Y, Kato T, Hosoi R, Kobayashi K, et al. Rat-PET study without anesthesia: anesthetics modify the dopamine D1 receptor binding in rat brain. Synapse. 2004;54:207-13. (Pubitemid 39532061)
26. Nicholas TE, Jones ME, Johnson DW, Phillipou G. Metabolism of the steroid anaesthetic alphaxalone by the isolated perfused rat lung. J Steroid Biochem. 1981;14:45-51. (Pubitemid 11131800)
27. Liu IM, Chang CK, Juang SW, Kou DH, Tong YC, Cheng KC, et al. Role of hyperglycaemia in the pathogenesis of hypotension observed in type-1 diabetic rats. Int J Exp Pathol. 2008;89:292-300. (Pubitemid 352019183)
28. Oliver JA, Clark L, Corletto F, Gould DJ. A comparison of anesthetic complications between diabetic and nondiabetic dogs undergoing phacoemulsification cataract surgery: a retrospective study. Vet Ophthalmol. 2010;13:244-50.
29. Oelze M, Knorr M, Schuhmacher S, Heeren T, Otto C, Schulz E, et al. Vascular dysfunction in streptozotocin-induced experimental diabetes strictly depends on insulin deficiency. J Vasc Res. 2011;48:275-84.
30. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol. 1994;266:E459-66.
31. Barragan JM, Rodriguez RE, Eng J, Blazquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept. 1996;67:63-8. (Pubitemid 26384196)
32. Isbil-Buyukcoskun N, Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept. 2004;118:33-8. (Pubitemid 38167364)
33. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43-52. (Pubitemid 34743464)
34. Edwards CM, Edwards AV, Bloom SR. Cardiovascular and pancreatic endocrine responses to glucagon-like peptide-1(7-36) amide in the conscious calf. Exp Physiol. 1997;82:709-16. (Pubitemid 27363855)
35. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3
36. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology. 2003;144:2242-52. (Pubitemid 36629873)
37. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 1996;45:832-5. (Pubitemid 26168585)